New investments

New investments
Colin Kerr
Colin Kerr
Published: Friday, September 13, 2019
VSY Biotechnology say the company has made new investments in order to make the supply chain network faster and more efficient in Germany. Mrs Özge Altunbaş Göktekin, the CEO of VSY Biotechnology  said : “In the global world, we are developing our networks to establish close relationships with our customers all over the world, regardless of geographical differences, using technology and logistics centers. The structure of our distribution networks integrates with technology. As an international company we export to about 60 countries. In line with our sustainable growth, we are improving our supply chain and logistics activities with each passing day. We set up both our new ordering system and our new logistics center in line with our aim to reach our customers in Europe much faster and deliver the products they want. We are increasing our speed in Europe with our new logistics center and online ordering system in Germany. Our European customers, who demand products from VSY Biotechnology, can instantly access orders on digital media and receive products in a very short time. We are working to maximize customer satisfaction with our innovative products and high-quality services, ” said Mrs Göktekin.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...